ImmunoVec is pioneering a new class of programmable DNA medicines that bring precision and durability to in vivo cell therapy. By combining programmable DNA with cell type-specific transcriptional control and novel targeted delivery technologies, the company's proprietary platform enables precise engineering of specific cell types directly within the body, unlocking a new generation of therapies for autoimmune diseases, cancers, and genetic disorders.
“We were looking for an investor who shared our long-term vision, and Black Diamond Ventures has been exactly that. From our very first meetings, the BDV team has brought thoughtful strategic guidance, been highly collaborative, and is a group we genuinely enjoy working with. As ImmunoVec enters its next chapter of growth, building on the momentum created by emerging from stealth, we’re excited to have BDV as partners as we continue advancing the next generation of programmable DNA medicines.”
– Ryan Wong, CEO and Co-Founder of ImmunoVec
